Document is current
Any future updates will be listed below
-
Authors
Kubo, Toshio
Kato, Hironari
Horiguchi, Shigeru
Kozuki, Toshiyuki
Asagi, Akinori
Yoshida, Michihiro
Udono, Heiichiro
Kiura, Katsuyuki
Hotta, Katsuyuki https://orcid.org/0000-0002-0112-0843
-
Funding
Funding for this research was provided by:
Ono Pharmaceutical
Okayama University
- License Information
-
More Information
Article History
Received: 26 December 2024
Accepted: 6 May 2025
First Online: 28 May 2025
Declarations
:
: TK received a research grant outside the current work from Chugai. KH received personal fees from AZ, Chugai, Lilly, MSD, BMS, Ono, Boehringer-Ingelheim, Nippon Kayaku, Amgen, Taiho, and Merck, and grants from MSD, AZ, Chugai, Lilly, BMS, Abbvie, and Ono. KK received honoraria from Chugai, AZ, Lilly, Taiho, BMS, Ono, MSD, Pfizer, Beohringer Ingelheim, Merck, Daiichi-Sankyo, Bayer, AMGEN, Eisai, Kyowa Hakko Kirin, Abbvie, Sanofi, LaboCorp Japan, IQVIA, and Gilead Sciences, and Research funding from Chugai, AZ, Lilly, Taiho, BMS, Ono, MSD, Pfizer, Beohringer Ingelheim, Merck, Nippon Kayaku, Novartis, Daiichi-Sankyo, Takeda, Bayer, Sawai, AMGEN, Eisai, and Abbvie. KK received research funding from Ono pharmaceutical. The authors declare no conflicts of interest regarding this study.
: This study was approved by the institutional review board of each participating hospital in accordance with the Declaration of Helsinki. The protocol summary, including participant and intervention details, has been previously described.
